Deuterium-enriched pioglitazone
The present application describes deuterium-enriched pioglitazone, pharmaceutically acceptable salt forms thereof, and methods of treating using the same.
1. A method of treating non-alcoholic steatohepatitis, comprising administering a therapeutically effective amount of a deuterium-enriched compound to a patient in need thereof to treat the non-alcoholic steatohepatitis, wherein the deuterium-enriched compound is
or a pharmaceutically acceptable salt thereof, wherein
R 1 and R 2 are independently selected from H and D, and R 3 -R 20 are H;
wherein the abundance of deuterium in R 1 is at least 30% and the abundance of deuterium in R 2 is at least 30%.
2. The method of claim 1 , wherein the abundance of deuterium in R 1 is at least 50% and the abundance of deuterium in R 2 is at least 50%.
3. The method of claim 1 , wherein the abundance of deuterium in R 1 is at least 50% and the abundance of deuterium in R 2 is at least 90%.
4. The method of claim 1 , wherein R 1 is D.
5. The method of claim 1 , wherein the deuterium enriched compound is administered as a pharmaceutical composition, the pharmaceutical composition comprising a pharmaceutically acceptable carrier and a therapeutically effective amount of the deuterium enriched compound or a pharmaceutically acceptable salt form thereof.
6. A method of treating non-alcoholic steatohepatitis, comprising administering a therapeutically effective amount of a deuterium-enriched compound to a patient in need thereof to treat the non-alcoholic steatohepatitis, wherein the deuterium-enriched compound is
or a pharmaceutically acceptable salt thereof, wherein R 1 and R 2 are independently selected from H and D, and R 3 -R 20 are H;
wherein the abundance of deuterium in R 1 is at least 30% and the abundance of deuterium in R 2 is at least 90%.
7. The method of claim 6 , wherein R 1 is H.
8. The method of claim 6 , wherein R 1 is D.
9. The method of claim 6 , wherein the deuterium enriched compound is administered as a pharmaceutical composition, the pharmaceutical composition comprising a pharmaceutically acceptable carrier and a therapeutically effective amount of the deuterium enriched compound or a pharmaceutically acceptable salt form thereof.